Healthcare Feb 01, 2021 02:41 PM (GMT+8) · EqualOcean
Zhuhai Beihai Biotechnology Co., Ltd. (hereinafter referred to as "Beihai biotechnology") has made significant progress. The company's independent research and development of bh009 docetaxel injection (excluding Tween 80) new drug clinical trial application (ind) has obtained the "drug clinical trial approval notice" issued by the State Drug Administration, and approved the clinical trial of bh009. The clinical trial will be solid tumor To provide a new and better treatment plan. Previously, bh009 was the first to obtain clinical trial approval in FDA. Beihai bio is a biomedical enterprise in the clinical stage, which is committed to the discovery and development of innovative drugs and improved new drugs, providing safer and more effective innovative anti-tumor drugs for patients all over the world. Through independent research and development, the company has 12 authorized invention patents and more than 70 invention patent applications. It has successfully developed a pioneering technology platform to improve the solubility of insoluble injections, and has more than 10 innovative drug pipelines for the treatment of tumor, pain and other major diseases.

This text is a result of machine translation.